| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Net loss from continuing operations | -1,333 | -1,964 | -1,212 | -1,585 |
| Net income from discontinued operations, net of taxes (notes 14, 15 and 16) | 40 | 42 | - | - |
| Net (loss) income | -1,293 | -1,922 | -1,212 | -1,585 |
| Less increase to accumulated deficit due to adjustment to common stock warrant exercise price | 0 | - | 1,005 | - |
| Less increase to accumulated deficit due to adjustment to preferred stock conversion price | 0 | 0 | - | - |
| Net (loss) income attributable to common stockholders | -1,293 | -1,922 | -2,217 | -1,585 |
| Basic (and diluted for net loss) (in shares) | 5,876,000 | 5,818,000 | 3,710,000 | 1,155,000 |
| Diluted earnings (loss) per share attributable to common stockholders (in shares) | 5,876,000 | 5,818,000 | - | - |
| Us-gaap_earningspersharebasic | -0.22 | -0.33 | -0.6 | -1.37 |
| Us-gaap_earningspersharediluted | -0.22 | -0.33 | - | - |
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)